A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ¿4 Non-Carriers

Project Details

StatusFinished
Effective start/end date14/11/11 → 30/11/15

Funding

  • Pfizer, Inc.: $10,025.00

Keywords

  • Aging & Alzheimers, Biotechnology & Drug Development